China (Mainland)
Brexpiprazole CAS NO.913611-97-9
- Min.Order: 1 Gram
- Payment Terms:
- Product Details
Keywords
- Brexpiprazole
- OPC-34712
- 7-[4-(4-benzo[b]thien-4-yl-1-piperazinyl)butoxy]- 2(1H)-Quinolinone
Quick Details
- ProName: Brexpiprazole
- CasNo: 913611-97-9
- Molecular Formula: C25H27N3O2S
- Application: rexpiprazole is a novel D2 dopamine pa...
- DeliveryTime: 4 weeks
- PackAge: 10g,25g,50g,100g
- Port: shang
- ProductionCapacity: 1 Kiloliter/Month
- Purity: 99%
- Transportation: by air
- LimitNum: 1 Gram
- Moisture Content: 0.1%
- Impurity: 0.1%
Superiority
Brexpiprazole also called OPC-34712) is a novel D2 dopamine partial agonist investigational product currently in clinical trials for the treatment of depression, schizophrenia, and attention deficit hyperactivity disorder (ADHD).[1]Although it failed Stage 2 trials for ADHD, it has been designed to provide improved efficacy and tolerability (e.g., less akathisia, restlessness and/or insomnia) over established adjunctive treatments for major depressive disorder (MDD).
Details
Brexpiprazole also called OPC-34712) is a novel D2 dopamine partial agonist investigational product currently in clinical trials for the treatment of depression, schizophrenia, and attention deficit hyperactivity disorder (ADHD).[1]Although it failed Stage 2 trials for ADHD, it has been designed to provide improved efficacy and tolerability (e.g., less akathisia, restlessness and/or insomnia) over established adjunctive treatments for major depressive disorder (MDD).
Biological Activity of Brexpiprazole
Brexpiprazole is a novel D2 dopamine partial agonist.
IC50 Value: N/A
Target: Dopamine Receptor
in vitro: Brexpiprazole (OPC-34712) is a close structural analog of aripiprazole and shares some of its pharmacological properties. Similarly to aripiprazole, brexpiprazole exhibits partial agonism of D2R and an enhanced affinity for specific serotonin receptors (e.g., 5-HT1A, 5-HT2A and 5-HT7). Currently
in vivo: Brexpiprazole is in Phase III clinical trials for patients with schizophrenia and as adjunctive therapy for patients with major depressive disorder
Product Name: Brexpiprazole
CAS Number：913611-97-9
Appearance：White solid
Assay：98～102%
Packing：5g;10g;25g;50g;100g;1kg
Usage： Brexpiprazole is a novel D2 dopamine partial agonist.
Biological Activity of Brexpiprazole
Brexpiprazole is a novel D2 dopamine partial agonist.
IC50 Value: N/A
Target: Dopamine Receptor
in vitro: Brexpiprazole (OPC-34712) is a close structural analog of aripiprazole and shares some of its pharmacological properties. Similarly to aripiprazole, brexpiprazole exhibits partial agonism of D2R and an enhanced affinity for specific serotonin receptors (e.g., 5-HT1A, 5-HT2A and 5-HT7). Currently
in vivo: Brexpiprazole is in Phase III clinical trials for patients with schizophrenia and as adjunctive therapy for patients with major depressive disorder